EAST WINDSOR, N.J. – Aurobindo Pharma’s valganciclovir for oral solution, are an AB-rated generic equivalent to the reference listed drug (RLD), VALCYTE for oral solution 50mg/1mL, manufactured by HOFFMANN LA ROCHE.

Valganciclovir for oral solution, are indicated for the prevention of Cytomegalovirus (CMV) disease in kidney and heart transplant patients at high risk.

Valganciclovir for oral solution, has an estimated market size of US $27.6 Million for the twelve months ending September 2022, as per IQVIA.